Prostate carcinoma cell lines and apoptosis: A review;Lignees de carcinome prostatique et apoptose: Etat de la question

Revue Medicale de Liege

Volumn 59, Issue 12, 2004, Pages 704-710

  Califice, S ^a   Waltregny, D ^a   Castronovo, V ^a   Van Den Brule F ^a,b  

^a CHU B35   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Apoptosis; Cancer; Prostate

Indexed keywords

ANDROGEN; CASPASE; CLUSTERIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P53; PROTEINASE ACTIVATED RECEPTOR 4;

ADULT; AGED; APOPTOSIS; CARCINOMA CELL; CELL PROLIFERATION; HUMAN; HUMAN CELL; MALE; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE CARCINOMA; REGULATORY MECHANISM; REVIEW; TUMOR GROWTH; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 12344285711     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Greenlee RT, Murray T, Bolden S et al.- Cancer statistics, 2000. CA Cancer J Clin, 2000, 50 (1), p. 7-33.
2. Gurumurthy S, Vasudevan KM, Rangnekar VM. - Regulation of apoptosis in prostate cancer. Cancer Metastasis Rev, 2001, 20 (3-4), p. 225-43.
3. Rokhlin OW, Bishop GA, Hostager BS et al.- Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res, 1997, 57 (9), p. 1758-68.
4. Zornig M, Hueber A, Baum W et al.- Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta, 2001, 1551 (2), p. F1-37.
5. Horoszewicz JS, Leong SS, Chu TM et al.- The LNCaP cell line - a new model for studies on human prostatic carcinoma. Prog Clin Biol Res, 1980, 37, p. 115-32.
6. Horoszewicz JS, Leong SS, Kawinski E et al.- LNCaP model of human prostatic carcinoma. Cancer Res, 1983, 43 (4), p. 1809-18.
7. Mickey DD, Stone KR, Wunderli H et al.- Characterization of a human prostate adenocarcinoma cell line (DU 145) as a monolayer culture and as a solid tumor in athymic mice. Prog Clin Biol Res, 1980, 37, p. 67-84.
8. Kaighn ME, Narayan KS, Ohnuki Y et al.- Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol, 1979, 17 (1), p. 16-23.
9. Iizumi T, Yazaki T, Kanoh S et al.- Establishment of a new prostatic carcinoma cell line (TSU-Pr1). J Urol, 1987, 137 (6), p. 1304-6.
10. Narayan P, Dahiya R.- Establishment and characterization of a human primary prostatic adenocarcinoma cell line (ND-1). J Urol, 1992, 148 (5), p. 1600-4.
11. Loop SM, Rozanski TA, Ostenson RC.- Human primary prostate tumor cell line, ALVA-31: a new model for studying the hormonal regulation of prostate tumor cell growth. Prostate, 1993, 22 (2), p. 93-108.
12. Muraki J, Addonizio JC, Choudhury MS et al.- Establishment of new human prostatic cancer cell line (JCA-1). Urology, 1990, 36 (1), p. 79-84.
13. Smith M, Kantoff P.- Molecular Biology of Prostate Cancer, in The Molecular Basis of CANCER, 2nd Edition, Mendelson et al, Editors. 2001. p. 343-360.
14. Tang DG, Porter AT.- Target to apoptosis: a hopeful weapon for prostate cancer. Prostate, 1997, 32 (4), p. 284-93.
15. Webber MM, Bello D, Quader S.- Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines. Prostate, 1997, 30 (1), p. 58-64.
16. Kajiwara T, Takeuchi T, Ueki T et al.- Effect of Bcl-2 overexpression in human prostate cancer cells in vitro and in vivo. Int J Urol, 1999, 6 (10), p. 520-5.
17. Shen Y, White E.- p53-dependent apoptosis pathways. Adv Cancer Res, 2001, 82, p. 55-84.
18. Finlay CA, Hinds PW, Tan TH et al.- Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol, 1988, 8 (2), p. 531-9.
19. Webber MM, Bello D, Quader S.- Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part 3. Oncogenes, suppressor genes, and applications. Prostate, 1997, 30 (2), p. 136-42.
20. Carroll AG, Voeller HJ, Sugars L et al.- p53 oncogene mutations in three human prostate cancer cell lines. Prostate, 1993, 23 (2), p. 123-34.
21. Isaacs WB, Carter BS, Ewing CM.- Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res, 1991, 51 (17), p. 4716-20.
22. Burchardt M, Burchardt T, Shabsigh A et al.- Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells. Prostate, 2001, 48(4), p. 225-30.
23. Nesslinger NJ, Shi XB, deVere White RW.- Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Res, 2003, 63 (9), p. 2228-33.
24. Schumacher G, Bruckheimer EM, Beham AW et al. - Molecular determinants of cell death induction following adenovirus-mediated gene transfer of wild-type p53 in prostate cancer cells. Int J Cancer, 2001, 91 (2), p. 159-66.
25. Yin DX, Schimke RT.- BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res, 1995, 55 (21), p. 4922-8.
26. Shi XB, Gumerlock PH, Muenzer JT et al.- BCL2 antisense transcripts decrease intracellular Bcl2 expression and sensitize LNCaP prostate cancer cells to apoptosis-inducing agents. Cancer Biother Radiopharm, 2001, 16 (5), p. 421-9.
27. Raffo AJ, Perlman H, Chen MW et al.- Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res, 1995, 55 (19), p. 4438-45.
28. Chen X, Thakkar H, Tyan F et al.- Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene, 2001, 20 (42), p. 6073-83.
29. Nesterov A, Lu X, Johnson M et al.- Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem, 2001, 276 (14), p. 10767-74.
30. Yuan XJ, Whang YE.- PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene, 2002, 21 (2), p. 319-27.
31. Marcelli M, Cunningham GR, Walkup M et al.- Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res, 1999, 59 (2), p. 382-90.
32. Panvichian R, Orth K, Pilat MJ et al.- Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line. Urology, 1999, 54 (4), p. 746-52.
33. Lebedeva I, Rando R, Ojwang J et al.- Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res, 2000, 60 (21), p. 6052-60.
34. Marcelli M, Marani M, Li X et al.- Heterogeneous apoptotic responses of prostate cancer cell lines identify an association between sensitivity to staurospoline-induced apoptosis, expression of Bcl-2 family members, and caspase activation. Prostate, 2000, 42 (4), p. 260-73.
35. Chakraborty M, Qiu SG, Vasudevan KM et al.- Par-4 drives trafficking and activation of Fas and Fas1 to induce prostate cancer cell apoptosis and tumor regression. Cancer Res, 2001, 61 (19), p. 7255-63.
36. Marcelli M et al.- Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res, 1998, 58 (1), p. 76-83.